ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025
Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up: A Real-Life Extension Study.Medicina (Kaunas, Lithuania) · 2026Article
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTirbanibulin is an approved topical treatment for actinic keratosis (AK). This non-interventional study investigated effectiveness and safety of tirbanibulin for AK. PATIENTS AND
methodsThe prospective KLIR-study was conducted at 58 German dermatology centers (02/2022-09/2023). Patients received tirbanibulin once daily for 5 consecutive days. Lesion count reduction, clearance rates, safety, and treatment satisfaction were assessed at day 57 (visit 3) after treatment. Visits on days 0, 8-29, and 240 allowed for the evaluation of baseline data, local skin reaction (LSR) peaks, and lesion recurrence, respectively.
resultsIn total, 545 AK patients were included in the study. The mean number of AK lesions decreased from 5.9 (baseline) to 1.9 at visit 3, representing a 70% lesion count reduction (p < 0.0001). Clearance rates at visit 3 were 37.4% (complete clearance) and 55.0% (partial clearance ≥ 75% reduction). Among patients with complete clearance at visit 3, 21.9% experienced recurrent AK lesions at visit 4. The majority of LSRs were mild or moderate. Erythema (97.6%) was the most common LSR. Overall, 91.5% of patients rated their AK lesions as improved and 99% would consider future tirbanibulin treatment ("definitely", "certainly", "probably", "maybe").
conclusionsTirbanibulin showed high lesion clearance and a high level of acceptance in real-life conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.